Therefore, researchers have attempted to develop efficient and reliable high-throughput screening assays to identify lead compounds for imaging proteinopathies such as tau, α-synuclein, and TDP-43 aggregates. This evidence concerns the gene TARDBP and proteostasis deficiencies.